Drugs / BIIB132
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05160558 | Feb 2022 → Jul 2023 | Machado-Joseph disease | Biogen | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIIB132 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05160558 ↗ |
| Modality | Antisense oligonucleotide | “anti-sense oligonucleotide” NCT05160558 ↗ |
| Route | Intrathecal | “BIIB132 administered via intrathecal (IT) injection” NCT05160558 ↗ |
| Target | ATXN3 | “developed to target ataxin-3 (ATXN3)” NCT05160558 ↗ |